Stanley Druckenmiller's COGT Position Overview
Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 0 shares of Cogent Biosciences, Inc. (COGT) worth $0, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Stanley Druckenmiller has maintained this position in COGT for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 1.15 M shares. Largest reduction occurred in Q1 2026, reducing 2.21 M shares.
Analysis based on 13F filings available since 2013 Q2
Stanley Druckenmiller's Cogent Biosciences (COGT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cogent Biosciences (COGT) Trades by Stanley Druckenmiller
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -2.21 M | Sold Out | 0 | $0.00 |
| Q4 2025 | +1.15 M | Add 109.00% | 2.21 M | $35.52 |
| Q3 2025 | +1.06 M | New Buy | 1.06 M | $14.36 |
Stanley Druckenmiller's Cogent Biosciences Investment FAQs
Stanley Druckenmiller first purchased Cogent Biosciences, Inc. (COGT) in Q3 2025, acquiring 1,059,580 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Stanley Druckenmiller has held Cogent Biosciences, Inc. (COGT) for 3 quarters since Q3 2025.
Stanley Druckenmiller's largest addition to Cogent Biosciences, Inc. (COGT) was in Q4 2025, adding 2,214,470 shares worth $78.66 M.
According to the latest 13F filing for Q1 2026, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 0 shares of Cogent Biosciences, Inc. (COGT), valued at approximately $0.
As of the Q1 2026 filing, Cogent Biosciences, Inc. (COGT) represents approximately 0.00% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.
Stanley Druckenmiller's peak holding in Cogent Biosciences, Inc. (COGT) was 2,214,470 shares, as reported at the end of Q4 2025.